CLDX Celldex Therapeutics, Inc.

NEUTRAL Impact: 4/10 Institutional Cluster
Horizon weeks Processed 3d 22h ago
Institutional cluster: 2 buyers, 3 sellers (mixed)

Executive Summary

A mixed institutional cluster in CLDX for Q3 2025 shows two mega-passive buyers (Wells Fargo, Invesco) adding modest positions totaling $1.6M, while three mega-passive sellers (Morgan Stanley, UBS, T. Rowe Price) trimmed $11.8M in holdings. The net selling pressure of ~$10.2M from passive rebalancing is notable but lacks active-manager conviction, suggesting routine portfolio adjustments rather than a fundamental thesis.

Key Financial Metrics

Direction
distributing
Buy Value
$3.8M
Sell Value
$11.8M
Net Flow
-$10.2M

Institutional Positions

Net institutional flow: -$10.2M

▲ Buyers (2)

InstitutionActionChangePosition ValueValue Δ
Wells Fargo ADD +56.6% $1.8M $872.0K
Invesco ADD +25.4% $2.0M $761.0K

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
Morgan Stanley TRIM -52.8% $13.5M -$5.4M
UBS TRIM -50.5% $17.1M -$6.3M
T. Rowe Price TRIM -37.6% $78.0K -$16.1K

Actionable Insight

The cluster is entirely passive — no active manager signal. The selling by Morgan Stanley and UBS may reflect index rebalancing or risk-management adjustments, not a negative thesis. Monitor next 13F for active-manager entries or exits; the lack of activist/hedge-fund interest keeps the stock in a wait-and-see posture.

Key Facts

  • 2 buyers added $1.6M in new holdings; 3 sellers reduced $11.8M
  • All five institutions are mega-passive (index/quant) — no active managers or hedge funds involved
  • Largest seller: UBS trimmed $6.3M (-50.5% of position); Morgan Stanley cut $5.4M (-52.8%)
  • Net aggregate change: -$10.2M, dominated by passive rebalancing
  • Historical reports on CLDX show 70% win rate at T+20 but negative alpha vs SPY (-5.21%)

Financial Impact

Net institutional selling of approximately $10.2M, with total selling value of $11.8M versus buying of $1.6M

institutional ownershipfloat

Risk Factors

  • Passive selling could continue if CLDX is underweighted in indices
  • No active-manager buying suggests limited catalyst-driven demand
  • Historical alpha vs SPY is negative (-5.21% T+20), indicating stock underperforms market on these signals

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
91% bullish (22 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-CLDX-2025-Q3
13 reports for CLDX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +11.09%Mar 27, 2026
Filters
Rows
Reports for CLDX — sortable, filterable
Type Now
Jun 14, 2026
today
Press Release
BEARISH ★ 6/10
awaiting T+20
Jun 14, 2026
1d ago
Press Release
BULLISH ★ 7/10
awaiting T+20
Jun 11, 2026
3d ago
Institutional Cluster
NEUTRAL ★ 4/10
$29.33 awaiting T+20awaiting T+20
Jun 10, 2026
4d ago
Press Release
NEUTRAL ★ 4/10
$29.33 awaiting T+20awaiting T+20
May 7, 2026
5w ago
8-K
MIXED ★ 6/10
$33.97 $28.62▼ −15.75%▼ −15.77%
May 7, 2026
5w ago
Press Release
MIXED ★ 6/10
$33.97 $28.62▼ −15.75%▼ −15.77%
Apr 6, 2026
9w ago
Press Release
NEUTRAL ★ 5/10
$31.37 $32.77▲ +4.46%▼ −4.52%
Apr 2, 2026
10w ago
Press Release
NEUTRAL ★ 5/10
$31.06 $32.88▲ +5.86%▼ −4.02%
Apr 1, 2026
10w ago
424B5
NEUTRAL ★ 5/10
$31.06 $32.88▲ +5.86%▼ −4.02%
Apr 1, 2026
10w ago
Press Release
NEUTRAL ★ 4/10
$31.06 $32.88▲ +5.86%▼ −4.02%
Showing 10 of 13

US Market Status

Market Closed — Opens in 2h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access